Kininogen-1 Active Protein | KNG1 active protein

Recombinant Human Kininogen-1 Protein

Cat. Num. AAA2556710

• Gene Names: KNG1; BK; BDK; KNG; HMWK
• Purity: >95% as determined by reducing SDS-PAGE.
• Synonyms: Kininogen-1; Recombinant Human Kininogen-1 Protein; lpha-2-Thiol Proteinase Inhibitor; Fitzgerald Factor; High Molecular Weight Kininogen; HMWK; Williams-Fitzgerald-Flaujeac Factor; KNG1; BDK; KNG; KNG1 active protein

• Host: Human Cells
• Purity/Purification: >95% as determined by reducing SDS-PAGE.
• Form/Format: Lyophilized from a 0.2 mum filtered solution of 20mM Hac-NaAC, 150mM NaCl, pH 4.0.
• Sequence Length: 644

• Species: Human
• Endotoxin: <1.0 EU per ug as determined by LAL test.
• Fragment: Gln19-Ser427
• Fusion Tag: C-6His
• Activity: Measured by its ability to inhibit papain cleavage of a fluorogenic peptide substrate Z-FR-AMC, R&D Systems, Catalog # ES009. The IC50 value is < 7 nM.
• Preparation and Storage: Lyophilized protein should be stored at < -20 degree C, though stable at room temperature for 3 weeks.; Reconstituted protein solution can be stored at 4-7 degree C for 2-7 days.; Aliquots of reconstituted samples are stable at < -20 degree C for 3 months.

Related Product Information for KNG1 active protein

Protein Construction: Recombinant Human Kininogen-1 is produced by our Mammalian expression system and the target gene encoding Gln19-Ser427 is expressed with a 6His tag at the C-terminus.

Background: Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn't involved in blood clotting.

NCBI and Uniprot Product Information

• NCBI GI #: 156231037
• NCBI GeneID: 3827
• NCBI Accession #: NP_001095886.1
• NCBI GenBank Nucleotide #: NM_001102416.3
• UniProt Accession #: P01042; P01043; Q53EQ0; Q6PAU9; Q7M4P1; A8K474; B2RCR2; C9JEX1
• Molecular Weight: Molecular Mass: 46.9kDa; Actual Protein Molecular Mass: 61kDa
• NCBI Official Full Name: kininogen-1 isoform 1
• NCBI Official Synonym Full Names: kininogen 1
• NCBI Official Symbol: KNG1
• NCBI Official Synonym Symbols: BK; BDK; KNG; HMWK
• NCBI Protein Information: kininogen-1
• UniProt Protein Name: Kininogen-1
• Protein Family: Kininogen
• UniProt Gene Name: KNG1
• UniProt Synonym Gene Names: BDK; KNG; HMWK

NCBI Description

This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. Bradykinin also functions as an antimicrobial peptide with antibacterial and antifungal activity. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2014]

Uniprot Description

1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.